Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

finance.yahoo.com · 2026-09-09

American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

TickrTrends take: Regeneron Pharmaceuticals operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. Fund activity such as selling decisions may reflect portfolio rebalancing or sector rotation rather than fundamental valuation concerns, given the company's current fair value standing. Investors focused on valuation should monitor whether any operational or pipeline developments might shift REGN's assessment from its present fairly valued position.

Read the full story at finance.yahoo.com →